Table 2.

Clinical information on the anemia management.

	MCO	High-flux	p
Number of patients using oral iron at baseline, n (%)	16 (66.7)	17 (68.0)	0.921
Number of patients using oral iron at 12 weeks, n (%)	16 (66.7)	17 (68.0)	0.921
Number of patients treated parenteral iron during study period, n (%)	3 (12.5)	8 (32.0)	0.102
Cumulative dose of parenteral iron per treated patients (mg)	600.0 ± 100.0	700.0 ± 297.6	0.426
Transfusion history during study period, n (%)	0	1 (4.0)	1.000
Used ESA type, n (%)			0.679
Epoetin alfa	13 (54.2)	17 (68.0)
Darbepoetin alfa	10 (41.7)	7 (28.0)
None	1 (4.2)	1 (4.0)

Data are shown as mean ± standard deviation or n (%). Difference was analyzed using Student’s t-test for continuous variables and Pearson’s chi-square test or Fisher’s exact test for categorical variables.

MCO, medium cut-off; ESA, erythropoiesis stimulating agent.